<DOC>
	<DOCNO>NCT00850564</DOCNO>
	<brief_summary>The purpose trial examine short-term effect Growth Hormone Releasing Hormone ( GHRH , tesamorelin ) administration healthy men . We hypothesize GHRH increase GH pulse height affect insulin sensitivity .</brief_summary>
	<brief_title>Effect Short Term Growth Hormone Releasing Hormone Healthy Men</brief_title>
	<detailed_description>The primary objective study determine effect growth hormone release hormone ( Tesamorelin ) endogenous overnight growth hormone secretion pulsatility , well insulin-stimulated glucose uptake . Healthy male subject receive 2mg Tesamorelin , subcutaneously , daily two week . At baseline two week treatment , assess overnight growth hormone frequent sample well insulin stimulate glucose uptake clamp . Subjects stop Tesamorelin return identical assessment 2 week withdrawal period .</detailed_description>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Growth Hormone-Releasing Hormone</mesh_term>
	<criteria>Men age 1860 year BMI &gt; 20kg/m2 &lt; 35kg/m2 Use antidiabetic agent , Megace , testosterone steroid use within 6 month study Use GH growth hormone stimulate peptide within six month start study Change lipid lower antihypertensive regimen within 3 month screen Fasting blood sugar &gt; 126 mg/dL , SGOT &gt; 2.5 time ULN , Hgb &lt; 12.0 g/dL , creatinine &gt; 1.4 mg/dL Carpal tunnel syndrome Severe chronic illness active malignancy history pituitary malignancy history colon cancer For men , history prostate cancer evidence prostate malignancy PSA &gt; 5 ng/mL Prior history hypopituitarism , head irradiation condition know affect GH axis Weight &lt; 110 lb .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>growth hormone release hormone</keyword>
</DOC>